866-997-4948(US-Canada Toll Free)

Immunology Partnering Terms and Agreements

Published By :

Current Partnering

Published Date : Jul 2013

Category :

Competitive Analysis

No. of Pages : 1159 Pages


The Immunology Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the immunology partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter immunology partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors immunology technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.

This report contains over 1,000 links to online copies of actual immunology deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. 

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in immunology dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.

Chapter 3 provides a review of the leading immunology deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of immunology deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides comprehensive access to all immunology deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all immunology partnering deals signed and announced since 2007. The chapter is organized by specific immunology therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all immunology partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in immunology partnering and dealmaking since 2007.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of immunology technologies and products.
Table of Content

Executive Summary

Chapter 1 Introduction

Chapter 2 Trends in immunology dealmaking
2.1. Introduction
2.2. Immunology partnering over the years
2.3. Bigpharma immunology dealmaking activity
2.4. Bigpharma not active in immunology 
2.5. Immunology partnering by deal type 
2.6. Immunology partnering by industry sector
2.7. Immunology partnering by stage of development
2.8. Immunology partnering by technology type
2.9. Immunology partnering by immunology indication
2.10. Average deal terms for immunology
2.10.1 Immunology headline values
2.10.2 Immunology upfront payments
2.10.3 Immunology milestone payments
2.10.4 Immunology royalty rates

Chapter 3 Leading immunology deals
3.1. Introduction
3.2. Top immunology deals by value
3.3. Top immunology deals involving bigpharma

Chapter 4 Bigpharma immunology deals
4.1. Introduction
4.2. How to use bigpharma partnering deals
4.3. Bigpharma immunology partnering company profiles
Abbott
Allergan
Amgen
Aspen Pharmacare
Astellas
AstraZeneca
Baxter International
Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Celgene
CSL
Daiichi Sankyo
Dainippon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Gilead Sciences
GlaxoSmithKline
Grifols
Johnson & Johnson
Lundbeck
Merck & Co
Merck KGaA
Mitsubishi Tanabe
Novartis
Novo Nordisk
Pfizer
Purdue
Roche
Sanofi
Servier
Shionogi
Takeda
Teva 
Valeant
Watson

Chapter 5 Immunology partnering contracts directory
5.1. Introduction
5.2. By deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market 
Contract service
Co-promotion 
Cross-licensing
Development 
Distribution 
Equity purchase 
Joint venture 
Licensing
Litigation
Loan
Manufacturing
Marketing
Option
Promotion
Research
Settlement
Sub-license
Supply
Termination
5.3. By stage of development
Discovery 
Formulation 
Marketed 
Phase I
Phase II 
Phase III 
Preclinical 
Regulatory 
5.4. By technology type
Antibodies 
Assays
Biological compounds 
Cell therapy
Devices 
Discovery tools
Drug delivery 
Enabling technology
Equipment 
Facilities 
Genomics 
In vitro models 
Natural product
Oligonucleotide
Orphan drug 
Packaging 
Peptides 
Processes 
Proteomics 
Recombinant DNA 
RNA therapeutics 
Screening 
Small molecules 
Stem cells 
Vaccines 

Chapter 6 Immunology dealmaking by indication
6.1. Introduction
6.2. Deals by therapeutic indication
Immunology
AIDS 
Allergy
Anaphylactic shock
Graft versus host disease
Inflammation
Systemic lupus erythematosus
Scleroderma
Chapter 7 Partnering resource center
7.1. Online partnering 
7.2. Partnering events 
7.3. Further reading on dealmaking

Appendices

Appendix 1 Directory of immunology deals by company A-Z 2007-2013 

Appendix 2 Directory of immunology deals by deal type 2007-2013

Appendix 3 Directory of immunology deals by stage of development 2007-2013

Appendix 4 Directory of immunology deals by technology type 2007-2013 

Appendix 5 Deal type definitions 
About Wildwood Ventures 
Current Partnering 
Current Agreements 
Recent titles from CurrentPartnering
Order Form Reports
Order Form Therapy Reports

List of Chart


Figure 1: Immunology partnering since 2007 
Figure 2: Bigpharma top 50 immunology deals 2007 to 2012
Figure 3: Bigpharma immunology deal frequency 2007 to 2012 
Figure 4: Inactive bigpharma in immunology 2007-2013 
Figure 5: Immunology partnering by deal type since 2007 
Figure 6: Immunology partnering by industry sector since 2007 
Figure 7: Immunology partnering by stage of development since 2007 
Figure 8: Immunology partnering by technology type since 2007
Figure 9: Immunology partnering by immunology target since 2007 
Figure 10: Immunology deals with a headline value 
Figure 11: Immunology deal headline value distribution, US$million discovery stage
Figure 12: Immunology deal headline value distribution, US$million preclinical stage
Figure 13: Immunology deal headline value distribution, US$million phase I stage
Figure 14: Immunology deal headline value distribution, US$million phase II stage
Figure 15: Immunology deal headline value distribution, US$million phase III stage
Figure 16: Immunology deal headline value distribution, US$million regulatory stage 
Figure 17: Immunology deal headline value distribution, US$million marketed stage 
Figure 18: Summary median headline value by stage of development, 2007-2013 
Figure 19 Immunology deals with upfront payment values
Figure 20: Immunology deal upfront payment distribution, US$million discovery stage
Figure 21: Immunology deal upfront payment distribution, US$million preclinical stage
Figure 22: Immunology deal upfront payment distribution, US$million phase I stage
Figure 23: Immunology deal upfront payment distribution, US$million phase II stage
Figure 24: Immunology deal upfront payment distribution, US$million phase III stage
Figure 25: Immunology deal upfront payment distribution, US$million regulatory stage
Figure 26: Immunology deal upfront payment distribution, US$million marketed stage
Figure 27: Summary median upfront payments by stage of development, 2007-2013
Figure 28: Immunology deals with milestone payments
Figure 29: Immunology deal milestone distribution, US$million discovery stage
Figure 30: Immunology deal milestone distribution, US$million preclinical stage
Figure 31: Immunology deal milestone distribution, US$million phase I stage
Figure 32: Immunology deal milestone distribution, US$million phase II stage
Figure 33: Immunology deal milestone distribution, US$million phase III stage
Figure 34: Immunology deal milestone distribution, US$million regulatory stage
Figure 35: Immunology deal milestone distribution, US$million marketed stage
Figure 36: Immunology deals with royalty rates, %
Figure 37: Immunology deal royalty rate distribution, US$million discovery stage
Figure 38: Immunology deal royalty rate distribution, US$million preclinical stage
Figure 39: Immunology deal royalty rate distribution, US$million phase I stage
Figure 40: Immunology deal royalty rate distribution, US$million phase II stage
Figure 41: Immunology deal royalty rate distribution, US$million phase III stage
Figure 42: Immunology deal royalty rate distribution, US$million regulatory stage
Figure 44: Summary median royalty rate by stage of development, 2007-2013
Figure 45: Top immunology deals by value since 2007
Figure 46: Top immunology deals signed by bigpharma value since 2007
Figure 47: Online partnering resources

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *